Provided by Tiger Trade Technology Pte. Ltd.

COYA THERAPEUTICS INC

5.04
+0.08001.61%
Post-market: 5.160.1200+2.38%18:56 EDT
Volume:145.19K
Turnover:738.67K
Market Cap:118.17M
PE:-4.63
High:5.22
Open:4.99
Low:4.98
Close:4.96
52wk High:7.75
52wk Low:3.71
Shares:23.45M
Float Shares:17.54M
Volume Ratio:1.44
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0897
EPS(LYR):-1.2700
ROE:-60.54%
ROA:-32.27%
PB:2.73
PE(LYR):-3.97

Loading ...

BTIG Reaffirms Their Buy Rating on Coya Therapeutics, Inc. (COYA)

TIPRANKS
·
Aug 12

Acumen Pharmaceuticals Q2 Net Loss Widens, Misses Analyst Estimates

Reuters
·
Aug 12

Annexon Biosciences Q2 Net Loss Widens, Cash Runway Extended

Reuters
·
Aug 12

Coya Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Coya Therapeutics Posts Investor Presentation on Treg-Directed Combination Therapy for Neurodegenerative Diseases

Reuters
·
Aug 11

Coya Net Loss Widens to $6.64 Million in Q2 FY26; R&D Expense Rises to $5.03 Million

Reuters
·
Aug 11

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
Aug 11

Coya Therapeutics Q2 EPS USD -0.28

THOMSON REUTERS
·
Aug 11

Coya Therapeutics Q2 Net Income USD -6.6 Million

THOMSON REUTERS
·
Aug 11

Coya Therapeutics Amends Filing to Name Mark Pavao to Audit Committee

Reuters
·
Aug 08

Coya Therapeutics Inc Expected to Post a Loss of 34 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI)

TIPRANKS
·
Jul 06

Coya Therapeutics Posts Investor Deck Outlining Treg-directed Combination Therapy Strategy for Neurodegenerative Diseases

Reuters
·
Jul 01

Coya Therapeutics Shareholders Approved Auditor Appointment for 2026 Fiscal Year

Reuters
·
Jun 26

H.C. Wainwright Remains a Buy on Coya Therapeutics, Inc. (COYA)

TIPRANKS
·
Jun 25

Coya Therapeutics presents ALSTARS Phase 2 trial design at ENCALS 2026 meeting

Reuters
·
Jun 18

Coya Therapeutics to host webinar on repetitive head trauma, brain inflammation and neurodegenerative disease

Reuters
·
Jun 15

Coya Therapeutics Says Phase 2 ALS Study Enters Blinded Extension Phase

MT Newswires Live
·
Jun 08

Coya Therapeutics Announces the First Cohort of Patients in the Alstars Trial Have Begun the Blinded Active-Treatment Extension Phase

THOMSON REUTERS
·
Jun 08

Coya Therapeutics Initiated at Buy by Roth Capital

Dow Jones
·
Jun 05